Chemistry: natural resins or derivatives; peptides or proteins; – Peptides of 3 to 100 amino acid residues – Synthesis of peptides
Reexamination Certificate
2005-09-09
2009-02-24
Kosar, Andrew D (Department: 1654)
Chemistry: natural resins or derivatives; peptides or proteins;
Peptides of 3 to 100 amino acid residues
Synthesis of peptides
C530S335000, C530S336000, C530S337000, C530S344000
Reexamination Certificate
active
07495072
ABSTRACT:
The subject invention provides an improved process for obtaining a mixture of polypeptides having nonuniform amino acid sequences, where each polypeptide consists essentially of alanine, glutamic acid, tyrosine and lysine where the resulting mixture of polypeptides comprises less than 0.3% brominated tyrosine and less than 1000 ppm metal ion impurities.
REFERENCES:
patent: 3846550 (1974-11-01), Teitelbaum et al.
patent: 3849550 (1974-11-01), Teitelbaum et al.
patent: 4264499 (1981-04-01), Hirai et al.
patent: 4594409 (1986-06-01), Hayashi et al.
patent: H1312 (1994-05-01), Coughlin et al.
patent: 5800808 (1998-09-01), Konfino et al.
patent: 5858964 (1999-01-01), Aharoni et al.
patent: 5872122 (1999-02-01), Bovy et al.
patent: 5981589 (1999-11-01), Konfino et al.
patent: 6048898 (2000-04-01), Konfino et al.
patent: 6054430 (2000-04-01), Konfino et al.
patent: 6214791 (2001-04-01), Arnon et al.
patent: 6342476 (2002-01-01), Konfino et al.
patent: 6362161 (2002-03-01), Konfino et al.
patent: 6514938 (2003-02-01), Gad et al.
patent: 6620847 (2003-09-01), Konfino et al.
patent: 6624180 (2003-09-01), South et al.
patent: 6800285 (2004-10-01), Rodriguez
patent: 6800287 (2004-10-01), Gad et al.
patent: 6939539 (2005-09-01), Konfino et al.
patent: 7022663 (2006-04-01), Gilbert et al.
patent: 7033582 (2006-04-01), Yong et al.
patent: 7049399 (2006-05-01), Bejan et al.
patent: 7074580 (2006-07-01), Gad et al.
patent: 7163802 (2007-01-01), Gad et al.
patent: 7199098 (2007-04-01), Konfino et al.
patent: 7279172 (2007-10-01), Aharoni et al.
patent: 2003/0170729 (2003-09-01), Klinger
patent: 2004/0091956 (2004-05-01), Bejan
patent: 2005/0256046 (2005-11-01), Gad et al.
patent: 2006/0122113 (2006-06-01), Pinchasi et al.
patent: 2006/0172942 (2006-08-01), Dolitzky
patent: 2007/0021324 (2007-01-01), Dolitzky
patent: 2007/0021341 (2007-01-01), Sela et al.
patent: 2007/0048794 (2007-03-01), Gad et al.
patent: 2007/0054857 (2007-03-01), Pinchasi et al.
patent: 3930733 (1991-03-01), None
patent: 0378246 (1990-06-01), None
patent: 1469826 (1995-11-01), None
patent: 1182051 (1985-09-01), None
patent: 1690368 (1990-08-01), None
patent: 1664845 (1991-07-01), None
patent: 9800375 (1998-01-01), None
patent: 9916747 (1999-07-01), None
patent: 9922402 (1999-09-01), None
patent: 9927107 (1999-11-01), None
patent: 0105198 (2001-02-01), None
patent: 0118248 (2001-06-01), None
patent: 0119649 (2001-06-01), None
patent: 02038859 (2002-12-01), None
patent: 03001744 (2003-11-01), None
patent: 2004036172 (2004-10-01), None
patent: 2005039003 (2005-10-01), None
patent: 2007072865 (2007-07-01), None
33% Hydrobromic acid in acetic acid product sheet BC0036 (Aug. 1999), 2 pages.
MSDS Hydrobromic acid 33-35%, in Acetic Acid. ACC#00739; Acros Organics N.V., created Jul. 22, 1999, revision #3 Mar. 18, 2003.
HunterLab “Insight on Color: APHA Q & A” (2003) 15(5) (Rev Feb. 2005), 4 pages.
HunterLab “Insight on Color: APHA” (1996) 8(16) (Rev May 2005), 3 pages.
U.S. Appl. No. 11/502,787, filed Aug. 10, 2006, Gad et al.
U.S. Appl. No. 11/373,794, filed Mar. 9, 2006, Pinchasi et al.
Aharoni, R., “Copolymer 1 inhibits manifestations of graft rejection,”Transplantation, Aug. 2001, 72(4), 598-605.
Bodanszky, M., “Principles of Peptide Synthesis,” Springer-Verlag, Berlin, Heidelberg, New York, Tokyo, 1984, 118-229.
Bornstein,Hosp. Pract.(Off. Ed.), May 15, 1992, vol. 27 (No. 5) L135-138, 141-142, 145-158.
Bornstein, “Cop 1 May be Beneficial for Patients with Exacerbating-remitting Form of Multiple Sclerosis”,Adv. Ther.(USA), 1987, 4, 206 (Abstract).
Bornstein, et al., “A Pilot Trial of Cop 1 in Exacerbating-remitting Multiple Sclerosis”,New Eng. J. Med., 1987, 317(7), 408-414.
Bornstein, et al., “A Placebo-controlled, Double-blind, Randomized Two-center, Pilot Trial of Cop 1 in Chronic Progressive Multiple Sclerosis”,Neurol., 1991, 41, 533-539.
Bornstein, et al., “Clinical Experience with COP-1 in Multiple Sclerosis”,Neurology, 1988 38 (Suppl. 2) 66-69.
Bornstein, et al., “Rationale for Immunomodulating Therapies of Multiple Sclerosis”,Neurology, 1988 38 (Suppl. 2) 80-81.
Bornstein, et al., “Clinical Trials of a Synthetic Polypeptide (Copolymer 1) for the Treatment of Multiple Sclerosis” in Gonsett et al.,Immunological and Clinical Aspects of Multiple Sclerosis(MTP Press, The Hague, 1984) 144-150.
Bornstein, et al., “Clinical Trials of Cop 1 in Multiple Sclerosis” inHandbook of Multiple Sclerosis(S.D. Cook Marcel Rekker, ed., 1990) 469-480.
Bornstein, et al., “Clinical Trials of Copolymer 1 in Multiple Sclerosis”,Ann. N.Y. Acad. Sci. (USA), 1984, 366-372.
Bornstein, et al., “Multiple Sclerosis: Clinical Trials of a Synthetic Polypeptide, Copolymer 1”,Neurol., 1985, 35 (Suppl. 1), 103 (Abstract).
Bornstein, et al., “Multiple Sclerosis: Trial of a Synthetic Polypeptide”,Ann. Neurol., 1982, 11, 317-319.
Bornstein, et al., “Pilot Trial of COP-1 in Chronic Progressive Multiple Sclerosis: Preliminary Report”, fromThe International Multiple Sclerosis Conference: An Update on Multiple Sclerosis, Roma (Italy), Sep. 15-17, 1988, in Elsevier Science Publisher, 1989, 225-232.
Bornstein, et al., “Treatment of Multiple Sclerosis with a Synthetic Polypeptide: Preliminary Results”,Ann. Neurol., 1980, 8, 117 (Abstract).
Bornstein, et al., “Treatment of Multiple Sclerosis with a Synthetic Polypeptide: Preliminary Results”,Trans. Am. Neurol. Assoc., 1980, 105, 348-350.
Bornstein, et al, “Treatment of Multiple Sclerosis with Copolymer 1” inTreatment of Multiple Sclerosis: Trial, Design, Reults and Future Perspectives(Rudick R.A. & Goodkin D.E., eds., Springer Verlag, London, 1992) 173-198.
Korczyn et al., “Safety profile of copolymer 1: Analysis of cumulative experience in the United States and Israel,”J. Neurol., Apr. 1996; 243 (4 Suppl 1) pp. S23-S26; and.
Teitelbaum D., Copolymer 1 induces T cells of the T helpe type 2 that crossreact with myelin basic protein and suppress experimental autoimmune encephalomyelitis,Proc. Natl. Acad. Sci. U.S.A., Sep. 1997, 94(20), 10821-10826.
U.S. Appl. No. 10/577,588, filed Oct. 28, 2004, Rosenberger et al.
U.S. Appl. No. 12/074,106, filed Dec. 22, 2008, Pinchasi.
“COPAXONE®” in Physician's Desk Reference, Medical Economics Co., Inc., Montvale, NJ, 2003, 3214-3218.
Copaxone® (glatiramer acetate injection), prescribing information, http://www.copaxone.com/pdf/PrescribingInformation.pdf.
PCT Written Opinion issued Oct. 9, 2007 for International Application No. PCT/US05/32395.
PCT International Search Report issued Oct. 9, 2007 for International Application No. PCT/US05/32395.
PCT International Preliminary Report on Patentability issued Oct. 30, 2007 for International Application No. PCT/US05/32395.
Cooper & Dunham LLP
Kosar Andrew D
Teva Pharmaceutical Industries Ltd.
White John P.
LandOfFree
Process for preparation of mixtures of polypeptides using... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Process for preparation of mixtures of polypeptides using..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Process for preparation of mixtures of polypeptides using... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4056233